B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Braxia Scientific Corp (OP: BRAXF )

0.0031 +0.0001 (+3.33%)
Streaming Delayed Price Updated: 2:34 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Braxia Scientific Corp

< Previous 1 2 Next >
I Saw Trillions Of Atoms In My Hand Vibrating At A Certain Frequency, Says Zappy Zapolin Describing His First Psychedelics Experience
Via Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Via Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Via Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC Pink: BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30,... 
Via Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Braxia Scientific Corp. 
Via Benzinga
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research 
Via Benzinga
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies  toward expected clinical studies targeting... 
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Irwin Naturals Inc. 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Research and telemedicine company Braxia Scientific Corp. (OTC: BRAXF) has filed its financial statements for the third quarter ended Dec. 
Via Benzinga
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Irwin Naturals Inc. (OTCQB: IWINF) (CSE:IWIN) (FRA:97X) has successfully completed the acquisition of Serenity Health, LLC, a ketamine clinic in Louisville, KY. The agreement with Serenity was... 
Via Benzinga
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Irwin Naturals Inc. 
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. 
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and... 
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.  
Via Benzinga
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
The season for psychedelics conferences is right around the corner. From very large and well-known events to small meets, this year’s remaining months are loaded with on-site and virtual discussions... 
Via Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and  
Via Benzinga
Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
A researcher and provider of ketamine-assisted treatments for mental health conditions, Braxia Scientific Corp. 
Via Benzinga
Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Braxia Scientific Corp. (OTCPK:BRAXF) (CSE:RAX) (FWB:4960) recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended... 
Via Benzinga
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment. 
Via Benzinga
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Braxia Scientific Corp. 
Via Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
The Week In Psychedelics: 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.